Australia’s recent decision to reschedule MDMA and psilocybin for therapeutic use represents a seismic shift in drug policy. The Therapeutic Goods Administration (TGA) has approved the prescription of these substances for specific psychiatric conditions, acknowledging their potential therapeutic benefits and enabling their use in a controlled medical context.